Clinical Trials Browser

Phase 2/3 × Dasatinib × Myeloid × Clear all

NCT00349518 2016-02-17

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Phase 2/3 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma